assayed can be added directly to the culture medium without prior extraction and only about 2-3 ml plasma is required for an assay. In general, very good agreement has been reported between the results of bioassay and radioimmunoassay measurements on individual plasma samples (Besser et al. 1972 , Frantz et al. 1972 ). By contrast, the local pigeon crop assay appears to give considerable overestimates of plasma prolactin levels and although it is still useful for the assay of purified hormone preparations, it cannot be regarded as suitable for the assay of plasma. Even in vitro mammary gland bioassays have a number of disadvantages. Their sample capacity is small, the methods are time-consuming, basal levels cannot usually be measured and responses may occur to two other human hormones with lactogenic activity, growth hormone and placental lactogen, although the use of appropriate antisera removes such interference. Despite this, they have enabled many useful clinical measurements to be made and do not require supplies of the still scarce human prolactin, as sheep prolactin is suitable as a standard. Further, it is important to be able to measure biological as well as immunological activity, at least in selected samples. For the future, it is hoped that radioligand assays, using prolactin receptor sites on plasma membranes (Turkington & Frantz 1972) will combine the advantages of bioassay and radioimmunoassay methods. 
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Radioimmunoassay of Human Prolactin
Only recently have immunological and other techniques demonstrated that prolactin is a separate entity from human growth hormone (HGH). For a routine radioimmunoassay three requirements must be met: first, an adequate supply of purified antigen for standard, labelling and immunization; secondly, a supply of specific antisera; and thirdly, a method for the separation of antibody-bound and free hormone. At present, the major problem with the radioimmunoassay of human prolactin is that the purified hormone is only available in very limited quantities. A num-ber of workers have partly overcome this by the use of assays based on prolactin from other species which may show a partial cross-reaction with human material (Bryant et al. 1971 , Hwang et al. 1971 , Jacobs et al. 1971 ). These assays are suitable for qualitative and in some cases quantitative estimations of circulating hormones. Only one truly homologous radioimmunoassay using purified prolactin for standard, labelling and immunization has been published (Hwang et al. 1971) .
The studies in our laboratory have been directed towards the establishment of a homologous radioimmunoassay for human prolactin designed for routine clinical use. Purified human prolactin was kindly supplied by Dr H Friesen and used for labelling and standard. Another preparation, described by Mr Davies & Dr Hartree (see p 862) was used for immunization. Antibodybound and free hormone were separated using a second antibody system. Labelled hormone (125L-human prolactin) was prepared by a modification of the chloramine-T method of Greenwood et al. (1963) . Various antisera were screened for use in the assay, including 22 to sheep prolactin, 11 to HPL and 18 to Raben HGH. All could bind labelled hormone but the resulting assays were not sufficiently sensitive to measure basal circulating levels of prolactin.
However, using an antiserum to the prolactin prepared by Mr Davies, a specific and sensitive radioimmunoassay for prolactin has been developed. In this system, HGH has only 0.01 % of the activity of prolactin, and other hormones tested show no cross-reaction. The minimum detectable level of prolactin in serum is 0.5 ng/ml and the assay has been applied to the measurement of prolactin in various physiological and clinical situations.
In normal females throughout the menstrual cycle levels varied between 6 and 50 ng/ml serum; no consistent pattern of release could be observed. The normal range in adult males was 6-25 ng/ml serum. During pregnancy there is a rise in circulating levels of prolactin in maternal serum (20-340 ng/ml) and high levels of prolactin (0.3-8 ,ug/ml) can be found in amniotic fluid. Prolactin release has been shown to occur after both suckling and injection of thyrotrophin-releasing hormone, with an increase of between two and twenty-fold over basal levels. In a series of 22 patients with galactorrhcea, serum levels varied between 35 and 1150 ng/ml; in no case was there a significant elevation of HGH levels. In 5 of these cases the levels fell during treatment with 2-Br-a-ergocryptine (CB 154) from 260-1000 to 8-40 ng/ml. These results confirm that human prolactin can be measured independently of HGH. The present method is sufficiently sensitive to measure levels of prolactin in all clinical and physiological situations so far investigated. However, routine establishment of the technique still requires that larger supplies of purified human prolactin are made available. . 1972) . Using this system, serum prolactin levels were found elevated in response to suckling during breast-feeding (L'Hermite, Stavric & Robyn 1972) , in cases of pathological galactorrheea, in response to psychotropic drugs such as sulpiride (L'Hermite, , and during pregnancy (L'Hermite & Robyn 1972).
A circadian periodicity of serum prolactin concentrations hag been described in both men and women , with a nocturnal discharge usually noticeable between 0100 and 0500 hours. In addition, when blood samples were collected every 30 min for a 24 h period additional episodic fluctuations of serum prolactin levels were observed, while the circadian discharge has been found to occur as early as 1900 or as late as 0800 hours (Vanhaelst et al. 1973 ). These observations, together with the very short disappearance half-life of this hormone from blood, make the interpretation of isolated prolactin determinations difficult. On the basis of such daily blood samples it has, however, been possible to demonstrate that prolactin concentrations follow a typical pattern during the normal menstrual cycle: mean levels (n= 18) are higher in the luteal than in the follicular phase and there is a midcycle modest peak (Vekemans et al. 1972).
This suggests that prolactin could be luteotrophic in humans as well as in animals.
Synthetic thyrotrophin-releasing hormone (TRH) induces systematically a release of prolactin as well as of thyrotrophin (TSH), suggesting that TRH could be a physiological prolactinreleasing hormone (l'Hermite, Stavric & Robyn 1972) . But there are various arguments against this hypothesis. TSH and prolactin circadian discharges are completely dissociated in time in some individuals (Vanhaelst et al. 1973) . Insulinic hypoglycemia results in a systematic response of prolactin but not TSH (Copinschi, L'Hermite, Vanhaelst et al. 1972 ). In patients with thyroid diseases, only those athyreotic ones have increased serum basal prolactin levels together with the highest TSH levels encountered (L'Hermite, Bonnyns et al. 1972) . Hypothyroidism and triiodothyronine treatment result in abolished TSH response to TRH with persistence of the prolactin response (L'Hermite, Bonnyns et al. 1972) .
A battery of tests is available for the investigation of the hypothalamopituitary axis with regard to prolactin secretion; insulinic hypoglycemia and TRH stimulate it, while it is inhibited by L-dopa and 2-Br-a-ergocryptine (CB 154). TRH and CB 154 are likely to act directly on the pituitary while the effects of L-dopa and insulinic hypoglycemia appear to be mediated through the hypothalamus, allowing a disturbance to be located (Copinschi, L'Hermite, Pasteels & Robyn 1972) .
CEstrogens are known to be potent stimulators of prolactin secretion in animals. When postmenopausal women with advanced breast cancer were treated with 3 mg per day ethinylcestradiol orally, initial serum prolactin levels were not significantly different from those of control menopausal women, while cestrogen treatment resulted in always significantly elevated prolactin levels (L'Hermite et al. 1973) . A survey of the problem of the role of prolactin in growth of human breast cancer suggests that a comparison should be made between the presence of receptors for cestrogens, prolactin-dependence and prolactin secretion, and the clinical response to treatment, whether hormonal or not.
